Cempra Inc (CEMP)

7.80
NASDAQ : Health Care
Prev Close 7.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.70 / 32.31
Avg Volume 2.07M
Exchange NASDAQ
Shares Outstanding 52.38M
Market Cap 392.86M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Decreases By 21.6% For CEMP

Short Interest Decreases By 21.6% For CEMP

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 2,124,430 share decrease in total short interest for Cempra Inc , to 7,727,618, a decrease of 21.56% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining

'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining

WOR is in a sweet spot for this rally, and NUE looks good, too, says Jim Cramer.

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

The number and magnitude of earnings surprises has a big impact on the markets, says Jim Cramer.

First Week of CEMP July 2017 Options Trading

First Week of CEMP July 2017 Options Trading

Investors in Cempra Inc saw new options become available this week, for the July 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period

SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period

Holzer & Holzer, LLC announces that a securities class action lawsuit has been filed against Cempra, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Cempra, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cempra, Inc.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Cempra, Inc.

Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote

Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote

By a slim 7-6 margin, experts convened by the FDA decided the benefits of solithromycin outweighed its potential safety problems in treating patients with community-acquired bacterial pneumonia.

Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review

Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review

JPMorgan analysts believe the safety concerns raised by the FDA after reviewing Cempra's (CEMP) Solithera drug could set 'a very high bar' for approval.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Cempra, Inc.

'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says

'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says

Jim Cramer says JCP is better, but 'just OK,' and investors should be careful with CEMP.

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer says the market can have many winners.